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Mycobacterium tuberculosis (Mtb) infection is a major international public health problem. One-third of the world’s population is
thought to have latent tuberculosis, a condition where individuals are infected by the intracellular bacteria without active disease
but are at risk for reactivation, if their immune system fails. Here, we discuss the role of nonspeciﬁc inﬂammatory responses
mediated by cytokines and chemokines induced by interaction of innate receptors expressed in macrophages and dendritic
cells (DCs). We also review current information regarding the importance of several cytokines including IL-17/IL-23 in the
development of protective cellular and antibody-mediated protective responses against Mtb and their inﬂuence in containment
of the infection. Finally, in this paper, emphasis is placed on the mechanisms of failure of Mtb control, including the immune
dysregulationinducedbythetreatmentwithbiologicaldrugsindiﬀerentautoimmunediseases.Furtherfunctionalstudies,focused
on the mechanisms involved in the early host-Mtb interactions and the interplay between host innate and acquired immunity
against Mtb, may be helpful to improve the understanding of protective responses in the lung and in the development of novel
therapeutic and prophylactic tools in TB.
1.Introduction
The contagious nature of tuberculosis (TB) was ﬁrst known
and described by Hippocrates and Galen. In the mid-
seventeenth century, Sylvius (Franc ¸ois de le Bo¨ e) and Ren´ e
Th´ eophile-Hyacinthe Laennec described the tubercle and
postulated that the tubercle was a common structure detect-
ed in all forms of the disease [1]. However, despite that the
etiological agent of the disease had not been identiﬁed, the
term “tuberculosis” was ﬁrst used by Sh¨ onlein in 1830 [2].
Fifty-two years later, in March 1882, Robert Koch reported
the discovery of the etiological agent that causes TB (the
tubercle bacillus) [1]. Probably this is one of the most
important events in the history of medicine.
Despite the scientiﬁc advances applied to the diagnosis
and treatment of Mycobacterium tuberculosis (Mtb) infec-
tion, it remains a signiﬁcant public health threat, particularly
in developing countries. One-third of the world’s population
isthoughttohavelatentMtbinfection[3],aconditionwhere
individuals are infected by the intracellular bacteria without
exhibiting the active disease but are at risk for reactivation.
According to WHO reports, 1.4 million of deaths were2 Clinical and Developmental Immunology
associated with TB in 2010 worldwide [4]. The incidence
of TB during 2010 worldwide was 8.8 million cases (128
cases/100,000 inhabitants), 59% of these cases were detected
in Asia and 26% in Africa. In Mexico, the reported incidence
was 18 cases/100,000 inhabitants, and 15,384 new cases were
diagnosed during 2010 [4].
It is generally accepted that primary infections with
Mtb produce active disease in approximately 10% of those
infected [5]. In the majority of the infected persons, Mtb
exists in the latent state, contained in the lungs, within
structures called granulomas. In this regard, host immune
mechanisms are involved in preventing the disease progres-
sion, and immune-compromised individuals are at a higher
risk of reactivating the disease [5, 6].
In this review, we will focus on the progress that has been
done in the host-Mtb interactions and the understanding
of innate and adaptive cellular and humoral mechanisms
involved in the pathogenesis of TB. We emphasize on Mtb-
host immunity interactions in a sequential list of events
trying to show a broad picture of the immunological aspects
involved in the pathogenesis of active TB. In this context,
we will discuss the role of toll-like receptors (TLRs) and the
connection with adaptive responses as central mechanisms
of protection from Mtb dissemination. The importance of
macrophages, dendritic cells (DCs), and IFN-γ producing
T cells in the early control of the Mtb infection and
the production of other regulatory and proinﬂammatory
cytokines such as IL-6, TNF-α, IL-12, and IL-23/IL-17 are
also reviewed [7–10]. In addition, we discuss recent ﬁndings
of the role of γ/δT and Th17 cells in the protective immune
response against the mycobacterial infections [11, 12]. We
also review recent literature of mechanisms that contribute
to the lack of Mtb infection control including mechanisms
of Mtb evasion of immune response, immune dysregulation
induced by autoimmune diseases and, the treatment with
anti-TNF-αdrugsandmechanismsofimmunologicalescape
inherent to the Mtb.
2. Pathogenesis of Tuberculosis
Based on experimental models, four events are well deﬁned
in the pathogenesis of pulmonary TB [13, 14].
(A) Inhalation of the Mtb. The early events following
inhalation of Mtb involve the engulfment of the bacilli by
alveolar macrophages and often their immediate killing by
diﬀerent macrophage bactericidal mechanisms, including
the generation of reactive nitrogen intermediates (RNI) and
reactive oxygen intermediates (ROI). The eﬃcacy of these
mechanisms depends on the intrinsic microbicidal capacity
of the alveolar macrophages, the pathogenic characteristics
of the inhaled Mtb strain, and the inﬂammatory microenvi-
ronment at the site of infection [15].
(B) Inﬂammatory Cell Recruitment. Bacilli which survive
proliferate logarithmically within alveolar macrophages and
DCs and induce the production of immune mediators such
as TNF-α, IL-6, IL-12p80, IL-1α,a n dI L - 1 β that activate
macrophagestoinduceearlybacterialkilling[5,16].IFN-γ is
aproinﬂammatorycytokineproducedbyCD4+andCD8+T
c e l l sa sw e l la sb ya c t i v a t e dN Kc e l l si nr e s p o n s et oI L - 1 2a n d
IL-18 produced by alveolar macrophages and DCs [15, 17–
19]. In a local lung inﬂammatory scenario induced by the
proliferation of Mtb, peripheral inﬂammatory cells, includ-
ing monocytes, neutrophils, and DCs, are recruited to the
lung [20, 21]. DCs are activated trough TLRs signaling, and
monocytes become diﬀerentiated to eﬀector macrophages
that produce microbicidal substances including TNF-α, that
contributes to the control of Mtb growth, and granuloma
formation [22].
(C) Control of Mycobacteria Proliferation. This phase is
characterized by the inhibition of the Mtb proliferation
with an eﬃcient cell-cell interaction and the formation of
a granuloma. As a result of chronic cytokine stimulation,
macrophages diﬀerentiate into epitheloid cells and become
fused giant cells [23]. The architecture of the granuloma
is characterized by the aggregation of T cells and infected
macrophages which contain the Mtb preventing their spread
[23–25]. In addition to the key role of proinﬂammatory
cytokines (e.g., IFN-γ,T N F - α, IL-6, IL-12, IL-17, and IL-
23) in the formation and stability of the granuloma, the
presenceofchemokinessuchasCCL2,CCL3,CCL5,CXCL8,
and CXCL10 is crucial for the recruitment of inﬂammatory
c e l l st of o r mg r a n u l o m a s[ 23, 26–28]. These mechanisms
allow the development of a localized primary TB infection
which eventually may become a stable (also known as a
latent) infection. In more than 90% of the latent infections,
the central caseous infectious foci containing live Mtb is
delimited by the granuloma walls. An active cycle of cellular
activation and suppression prevents the replication and
spreading of the Mtb [5, 29].
(D) Post-Primary Tuberculosis. As a result of the mycobac-
teria persistence, associated with a failure in the immuno-
surveillance system, latent disease may be reactivated,
inducingthedamageofnearbybronchiandconditioning the
spreadingoftheMtbtootherareasofthelung[30],Figure 1.
3. Role of TLRs in the Control of Mtb Infection
The control of Mtb infection begins with the recognition
of mycobacterial structural components of the cell wall
such as mycolic acids, peptidoglycans, arabinogalactins,
phosphatidyl-myo-inositol mannosides (PIM), mannose-
capped lipoarabinomannan (Man-LAM), lipomannan, and
mannoglycoproteins [31, 32]. The recognition of conserved
molecular patterns is possible through pattern recognition
receptors (PRR), among them the best known are the TLRs,
nucleotide-binding oligomerization domain-like receptor
(NLR), C-type lectins, and scavenger and complement
receptors [33–36].
The interaction of Mtb conserved molecular patterns
with the PRR triggers the activation of diverse innate immu-
nity mediators involved in the phagocytosis of mycobacteriaClinical and Developmental Immunology 3
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Figure 1: Pathogenesis of tuberculosis. TB pathogenesis can be divided in four well-deﬁned events. Inhalation of the mycobacteria is followed
by its interaction with resident macrophages through cellular receptors and its internalization. Macrophage bactericidal mechanisms are
thenactivated, including RNI and ROI generation. Theeﬃcient killingof mycobacteria depends on pathogen and host factors. Inﬂammatory
cell recruitment: survived mycobacteria proliferate within macrophages inducing the production of proinﬂammatory cytokines. The local
inﬂammatory environment induces the recruitment of several cell types including monocytes, neutrophils, and dendritic cells to the site of
infection. High levels of TNF-α contribute to control Mtb growth and granuloma formation. Control of mycobacteria proliferation: arrival of
immune cells to the site of infection including T cells, which become organized in characteristic structures called granulomas eﬃciently stop
mycobacteria proliferation and contain the mycobacteria within the granuloma walls preventing its spread. Characteristic of this structure
is the presence of foam cells resulting from the diﬀerentiation of chronically activated macrophages. Mycobacteria containment eventually
becomes stable (latent) infection. Postprimary TB: mycobacteria persistence associated with a failure in the immunosurveillance system
increases the risk that latent disease becomes reactivated, inducing the damage of nearby bronchi and conditioning the spreading of the Mtb
to other areas of the lung and the transmission of the disease.
and signaling pathways related to the IL-12, TNF-α,a n dI L -
1β production [36, 37].
TLRs are a family of phylogenetically conserved genes
which are essential for recognition of a broad repertoire of
microbes on macrophages and DCs. It is well accepted that
TLR2, TLR4, and TLR9 play an important role in the innate
responses against Mtb [38–41], Figure 2.
TLR2 forms dimers with TLR1 or TLR6 which recognize
diacylated or triacylated lipoproteins. In addition, lipoara-
binomannan (LAM), lipomannan (LM), and phosphatidyli-
nositol mannoside (PIM) from Mtb may also be recognized
by TLR2 [22, 41]. Importantly, despite in vitro evidence that
TLR2is important inthecontrolofseveralaspectsofeﬀector
functions of antigen presenting cells, it has been demon-
strated that TLR2 deﬁciency in experimental models does
not aﬀect the development of secondary immune responses
to Mtb [42–46].
The cell wall of gram-negative bacteria constituent lipo-
polysaccharide (LPS), a potent proinﬂammatory pathogen-
associated molecular pattern, is the ligand for TLR4 receptor,
Figure 2. LPS recognition by TLR4 induces the expression
of NF-kB and regulates the production of proinﬂammatory
cytokines and chemokines including IL-1, IL-6, and CXCL8
[39, 47–50].
The critical role of TLR4 in the development of eﬃcient
innate host responses to mycobacteria has been demon-
strated in functional studies in mice. TLR4-deﬁcient C3H/
HeJ mice are more susceptible to develop lethal Mtb-
infection compared with normal C3H/OuJ mice [47]. Fur-
thermore, the expression of TNF-α, IL-12p40, and CCL2 in
lung and in Mtb infected cultures from TLR4-deﬁcient C3H/
HeJmiceisimpairedwhencomparedwithnormalmice[48].
The importance of TLR9 in the recognition of bacterial
unmethylated CpG motifs has been also demonstrated in4 Clinical and Developmental Immunology
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Figure 2: TLRs signaling pathways involved in the recognition of Mtb structures.TLR receptors can recognize several conserved molecular
patterns of the mycobacteria cell wall. Diacylated or triacylated proteins as well as LPS are recognized by membrane receptors (TLR1, TLR2,
TLR6,andTLR4),whereasbacterialunmethylatedCpGDNAcanberecognizedbyendosomalTLR9.MyD88adaptorisacentralcomponent
in TLR signaling whose downstream signaling cascade leads to the activation of NF-kB and AP-1 transcription factors and to the production
of inﬂammatory cytokines. Signaling through TRIF adaptor molecule activates IRF-3 transcription factor inducing IFN-β secretion.
TLR9-deﬁcient mice [37, 38, 51]. In vitro s t u d i e sh a v ec o n -
ﬁrmedthatstimulationthroughTLR9inducesIL-12produc-
tion by DCs [38]. On the other hand, conﬂicting evidence
from experimental studies has shown that macrophages
obtained from triple knockout mice TLR2-TLR4-TLR9 dis-
play similar capacity to the wild type mice to control Mtb
[38].
The variability in the outcome of Mtb infection in single,
double, or triple TLR2-, TLR4-, and TLR9-deﬁcient mice
may be due to diﬀerences in the Mtb strains used or due to
diﬀerences in the genetic background and functional immu-
nity of mice strains used in diﬀerent studies. Contrasting
with the controversial results on the role of TLRs in the
innate control of Mtb infection, a growing body of evidence
supports the essential role of the myeloid diﬀerentiation fac-
tor 88 (MyD88) in the development of protective responses
against Mtb [52, 53]. MyD88 is a key signaling adapter in
TLRs signaling [52, 53]; MyD88 binds to the cytoplasmic
portion of TLRs and associates with IRAK-4 and IRAK-
1 through the interaction of their death domains. IRAK-4
phosphorylates and activates IRAK-1 that in turn associates
with TRAF6 leading to its oligomerization and activation.
Posterior binding of Ubc13 and Uev1A promotes TRAF6
ubiquitination, TAB2 recruitment, and TAK1 activation
assembling a larger complex leading to the activation of
the transcription factors NF-kB and AP-1 [22, 54], Figure 2.
MyD88-deﬁcient mice are highly susceptible to infection by
several pathogens including Mtb [55–58].
Recentevidencesuggeststhatinteractionofearlysecreted
antigenic target protein 6 (ESAT-6) with TLR-2/MyD88
eﬃciently induces the diﬀerentiation of Th17 cell protective
responses against Mtb [59]. In addition, MyD88 is also
involved in the signaling cascades from receptors of IL-1β
and IL-18 [60–62]. In this context, mice deﬁcient for IL-18
promptly develop a lethal H37Rv strain Mtb infection when
compared with wild-type and TLR2-TLR4 double knockout
mice. IL-18-deﬁcient mice also exhibit a signiﬁcant impaired
Th1 response [63].
In addition to the TLRs, other mechanisms of innate
immunity that are not discussed in this review suchClinical and Developmental Immunology 5
as NOD2- and NOD-like receptors, C-type lectin recep-
tors,multiproteincomplexesalsocalledinﬂammasomes,and
vitamin D have been extensively studied [64].
4. CytokinesandChemokines Producedin
Response to Mtb Infection
Chemokines are a large family of structurally related pro-
teins that regulate inﬂammation, immune cell traﬃcking,
and diﬀerentiation through their interaction with 7-trans-
membrane G-protein coupled receptors. Chemokines have
been grouped according to structural similarities and the
presence of conserved cysteine residues. The chemokines
with two of four consecutive cysteine residues are known
as CC chemokines, whereas CXC chemokines have one
aminoacid between the ﬁrst two of four cysteine residues.
C chemokines, with one cysteine, at the amino terminus
and CX3C chemokines containing three intervening amino
acids have been described. The receptors are designated by
the chemokine class to which it binds, followed by the letter
“R” and a chronological number [65]. The contribution
of chemokines in the control of Mtb infection has been
supported by several in vitro and in vivo studies [20, 66,
67]. Once the macrophage engulfs Mtb, it produces several
cytokines and chemokines which induce the development of
proinﬂammatory responses. Mtb infection of macrophages
induces the production of various chemokines including
CCL2, CCL3, CCL5, CCL7, CCL12, CXCL2, CXCL8, and
CXCL10[67].Thesechemokinesarecloselyrelatedwithacti-
vation of microbicidal responses promoting the migration
of diﬀerent cell subpopulations to the Mtb-infected tissues
to form granulomas [68]. Several studies have investigated
the eﬀects of chemokines in the function and recruitment of
monocytes following the infection with Mtb. They promote
monocytes, DCs, activated macrophages, polymorphonu-
clear cells (particularly neutrophils), and T lymphocytes
migration to bronchoalveolar spaces during pulmonary TB
[69].
Inﬂammatory monocytes inﬁltrates are signiﬁcantly
reduced in CCR2-deﬁcient mice infected with Mtb. During
TB infection in normal mice, recruited monocytes express
CCR2 which has diﬀerent agonists, CCL2, among them [70].
In line with these observations, it is accepted that CCL2
is a central activator of macrophages. Secreted chemokines
play a signiﬁcant role in the recruitment of eﬀector T cells
to the site of Mtb infection [71]. In vitro analysis has
demonstrated that TLRs (TLR1, TLR2, TLR3, TLR4, and
TLR-9) are relevant in the signaling for CCL2 induction
through diﬀerent transcription factors including NF-kB and
MAP kinases [72, 73]. A direct correlation between elevated
CCL2 levels in TB and severity of the disease has been
recently reported [74]. Importantly, CCL2 exerts functional
activity in the recruitment of both Th1 and Th2 cells and
facilitates the polarization of na¨ ıve T cells to Th2 cells as
a result of IL-4 upregulation. In this perspective, increased
CCL2 levels may promote an excessive polarization to Th2
responses, resulting in a defective control of Mtb infection
[75–77].
CCL5 is a chemokine produced by a variety of cells
including macrophages, ﬁbroblasts, eosinophils, endothelial
cells, and platelets. CCL5 exerts chemotactic activity on
DCs, T lymphocytes, polymorphonuclear cells, NK cells, and
mast cells to inﬂamed or infected tissues. The expression
and functional activities of CCL5 have been studied in
experimental models of infection with mycobacteria. CCL5
blockade aﬀects the recruitment of cells and the formation
of granulomas induced by M. bovis antigens [78, 79]. CCL5
is important in early responses to Mtb due to its role in the
recruitment of IFN-γ producing T cells to form lymphocyte-
enriched granulomas [79]. In contrast, there is one study
thatsuggestedthatCCR5andtheirligands(includingCCL5)
are not essential to the development of protective responses
to Mtb. In this study, signiﬁcant diﬀerences in the response
to the pathogenic H37RV strain of Mtb between CCR5-
deﬁcient mice and wild-type mice were not detected [80].
The eﬃcient induction of Th1 immunity is decisive for
the defense against Mtb. The classical cytokines produced in
response to Mtb infection are IL-2, IFN-γ,I L - 6 ,I L - 1 α/β,I L -
12, and TNF-α [17, 18, 81–84].
4.1. TNF-α. This cytokine mediates early inﬂammatory
responses against pathogens and is produced by a variety
of cells including macrophages, lymphocytes, neutrophils,
mast cells, and endothelial cells. Several functions have been
attributed to TNF-α, but probably one of the most relevant
functions is the regulation of the inﬂammatory response,
stimulatingtheproductionofIL-1andIL-6[15].Theimpor-
tance of TNF-α in the defense against Mtb was established by
the increased susceptibility to BCG infection in mice treated
with anti-TNF-α antibodies [85, 86]. The mechanisms of
Mtb susceptibility associated with the use of TNF blockers
will be discussed in one of the next sections of this review.
TNF-α contributes in the control of Mtb infection by the
induction of RNIs and ROIs by macrophages and early
induction of chemokines. TNF-α-deﬁcient mice produce
reduced levels of chemokines resulting in defective granu-
loma formation [87].
4.2. IFN-γ. The function of IFN-γ in response to pathogens
has been extensively studied and is critical in the regulation
of T cell responses in mycobacterial disease [9]. IFN-γ is
produced by activated T cells, NK cells, and macrophages,
and it is essential for the activation of phagocytes and
antigen presentation, and it promotes cellular proliferation,
cell adhesion, and apoptosis. In macrophages, IFN-γ induces
respiratory burst contributing to the production of RNIs
and ROIs [9]. In addition, activated macrophages produce
immunomodulatory and chemotactic molecules that pro-
mote upregulation of TNF-α receptor and NRAMP-1. The
production of large amounts of ROIs and NO by innate
immune cells is considered one of the most important eﬀects
of IFN-γ.Inthemicemodel ofMtbinfection,NOisessential
in the killing of Mtb by mononuclear phagocytes. In NO
synthase 2 gene-deﬁcient mice (iNOS−/−), the infection
with Mtb has a rapid progression and a higher rate of
mortality [88, 89]. Marked defects in the IFN-γ-signalling6 Clinical and Developmental Immunology
pathways, observed in IFN-γ deﬁcient mice, provoke high
susceptibility to mycobacterial infections. These mice also
fail to develop granulomas following aerosol Mtb infection
withasigniﬁcantimpairmentofmacrophageactivation[90].
4.3.IL-6. Itisacytokinewithawidevarietyoffunctionsthat
can exert pro- or anti-inﬂammatory eﬀects and it is critical
to the development of early inﬂammatory mechanisms. IL-6
is also involved in the development of T and B lymphocyte
responses and hematopoiesis and is secreted by diﬀerent
cell types, including B and T cells, phagocytes, ﬁbroblasts,
and endothelial cells [91–93]. IL-6 is produced in response
to Mtb in early phases of the infection. The absence of
this cytokine in the low dose of Mtb mice model infection
promotes a delayed IFN-γ response in the lung and a slight
increase in the Mtb burden [94, 95].
T h ee v i d e n c es u p p o r t st h ei d e at h a tI L - 6i sc r i t i c a li n
the modulation and maintenance of the IL-17-producing
cells in response to Mtb infection in mice [96]. In addition,
IL-6 and IL-12 are critical in the development of eﬃcient
T lymphocyte antimycobacterial responses, and IFN-γ-
mediated responses against Mtb following vaccination with
the short-term-culture ﬁltrate (ST-CF) antigens from Mtb
[97].
4.4. IL-12. Mtb eﬃciently promotes the production of IL-
12p40 subunit. IL-12 is a cytokine that promotes the
development of Th1 responses and is rapidly produced by
DCsthroughtheinteractionofMtbwithTLRs.Interestingly,
some studies have suggested that induction of IL-12 produc-
tion is dependent on TLR9 in DCs and that it is dependent
on TLR2 in macrophages [98]. Importantly, it has been
demonstrated that murine macrophages release signiﬁcantly
lower IL-12 amounts than DCs in response to Mtb infection
[99, 100]. IL-12 deﬁciency increases the susceptibility to
mycobacterial disease in humans [101].
4.5. IL-23/IL17. Recent studies have demonstrated that the
IL-23/IL-17 pathway may have a crucial role in the immunity
against several pathogens, particularly in mycobacterial
infection [26, 102]. These cytokines have been involved
in the development of protective and regulatory immune
responses in mice and humans infected with Mtb. The role
of IL-17 in the development of antimicrobial responses,
chemokine production, and recruitment of inﬂammatory
cells for control of pathogens has been described in several
studies [27, 103–105]. In M. bovis BCG infection, the
absence of IL-17 does not inﬂuence the overall survival or
susceptibility to infection but has an eﬀect in the formation
of granulomas in the lung [106]. In consonance, recent
ﬁndings indicate that IL-23 is not determinant for the early
control of Mtb infection but is required for the development
and maintenance of Th17 responses to Mtb [107].
5.TCellResponses inTB
As we mentioned before, the control of Mtb infection in
the lung depends on the development of eﬃcient innate
and adaptive responses. CD4+, CD8+, and γδTl ym p h o c yt e s
play an important role in the protection from Mtb [15].
CD4+ T cells produce immune mediators (IFN-γ,I L - 2 ,
and lymphotoxin alpha) [108] CD8+ T cells, and γδT
cells release granzymes and perforins that exert a direct
eﬀect on mycobacteria and infected cells through Fas ligand
dependent and independent mechanisms. Peripheral T cells
recognize Mtb antigens (ESAT-6 and Mtb-39) which stimu-
late the production of IFN-γ and TNF-α [12, 17, 109]
It has been established that the development of eﬀector
T cell responses requires the dissemination of live bacteria
or bacterial antigens presented by DCs that upregulate the
expressionofCCR7andmigratetothedraininglymphnodes
[110, 111]. It is possible that other cell types also contribute
in the transport of Mtb antigens to the lymph nodes. In this
regard, some studies have suggested that neutrophils trans-
port live BCG to draining lymph nodes after intradermal
vaccination [112]. The proliferation of na¨ ıve Mtb-speciﬁc T
cells occurs ﬁrst in the draining lymph node in response to
the dissemination of Mtb [113]. Once the antigen-speciﬁc
T cells become activated through the presentation of Mtb
antigens on MHC class I and class II on the surface of
antigen-presenting cells, they migrate to the primary areas
of infection in the lung 15–18 days after infection [114].
Mtb infection might aﬀect the migration of DCs to the
draining lymph nodes by the induction of IL-10 production
[115]. Interestingly, high numbers of antigen-speciﬁc CD4+
CD69+ Th1 cells against ESAT-6 and CFP-10 peptides have
been detected in pleural ﬂuid from patients with pleural TB.
Inthisstudy,theauthorssuggestthatbasedontheexpression
of CD69 on Th1 antigen speciﬁc cells, CD69 is a useful
marker to identify antigen speciﬁc Th1 responses in patients
with TB [116].
The development of eﬃcient memory CD4+ and CD8+
T cell responses is the main goal of the novel vaccine strate-
gies against Mtb. In addition to the importance of CD4+ and
CD8+ T cells in TB, a growing body of evidence supports
the importance of γδT cells in the cellular immunity against
mycobacterial infections. Recent reports have shown that
patientswithactiveTBhavereducedlevelsofVγ9/Vδ2Tcells
when compared with healthy donors [11]. The mechanisms
explaining how γδT cells inﬂuence the innate or acquired
responses against Mtb are not completely understood. Nev-
ertheless, γδTl y m p h o c y t e sa r eam a j o rs o u r c eo fI L - 1 7
and IFN-γ, key cytokines in the proinﬂammatory responses
and chemokine regulation. In mice, the absence of IL-17
provokes a signiﬁcant reduction in the mononuclear and
polymorphonuclear inﬂammatory inﬁltrates to the lung [26,
117, 118]. In our published studies, overexpression of IL-
17 was found in peripheral mononuclear cells from latent
tuberculosis individuals [119].
These ﬁndings need to be explained in regards to the
controversy related to the discrepancies found in the Th1/
Th2 paradigm [120]. In addition, the studies of the inﬂuence
of microbiome diversity in the driving of immunity against
Mtb could be helpful to understand the variability of innate
and acquired responses, particularly Th1 or Th2 phenotypes
observed in Mtb-exposed individuals [121, 122].Clinical and Developmental Immunology 7
Several studies have supported the role of IL-23 and IL-
17intheformation,maintenance,andlong-termintegrity of
granuloma in advanced stages of the inﬂammatory process
induced by Mtb. Diﬀerentiation of Th17 cells depends on
the production of IL-23, IL-1β,I L - 6 ,a n dT N F - α.T h e
importance of Th17 cells is illustrated by the fact that
defective production of Th17-related cytokines inﬂuences
the outcome of the infection [117, 123–127].
Human natural killer (NK) cells are important in the
innate defense against pathogens [128], and they also
mediate antimycobacterial activity. NK cells express surface-
bindingproteinsthathavethecapacitytobindligandsonthe
surface of most cells. The interplay between stimulatory and
inhibitorysignalsdeterminesthefunctionalactivationofNK
cells. Previous studies have demonstrated that human NK
cells can recognize and lyse macrophages infected with Mtb
using the NKp46 receptor [129]. It has been demonstrated
that once the human macrophages become infected, they
upregulate vimentin, and NK cells can lyse them via ligation
of the vimentin with the activator NKp46 receptor [130].
In addition to the role of activated NK cells in the lysis
of infected cells, they also produce signiﬁcant amounts of
IFN-γ, IL-22, and other cytokines. A direct eﬀect of IL-22
produced by IL-15 and DAP-10-stimulated NK cells in the
control of Mtb proliferation has been described [131].
6. HumoralMechanisms Possibly Involvedin
LatentTuberculosis Infection
We have summarized the accepted evidence that innate and
adaptive cell-mediated immunity (CMI) plays a pivotal role
in the response to Mtb infection in experimental models
and humans. In this section, we will discuss published per-
taining evidence about the role of humoral immunity in
the protection and control of Mtb infection. Supportive
information about the importance of antibodies in the host
defense against mycobacterial infections has been provided
by experimental studies in both animals and humans which
demonstrate that speciﬁc antibodies neutralize pathogen
toxins, promote opsonization, and modulate complement-
mediated lysis. Several authors have reported the use of
ELISA assays to measure titers of IgG speciﬁc to mycobac-
terial antigens in adult patients with pulmonary TB [132]
and children with disseminated TB [133]. In the ﬁrst study
of adults with TB, those patients who received anti-TB
treatment for 4 weeks or more exhibited higher IgG titers
when compared with patients who received less than 4-
week treatment. Furthermore, children with disseminated
TB had lower levels of IgG against mycobacterial antigens
than children with localized infection. In addition, the levels
of IgG anti-PPD antibodies in TB-HIV patients varies with
the stage of HIV infection, indicating a progressive impair-
ment of the antibody responses in advanced stages of
HIV infection [134]. Another study, in HIV-TB coinfected
individuals, reported signiﬁcant diﬀerences in the titers of
LAM-speciﬁc IgG1, IgG2, and IgG4 subclasses between HIV-
TB and TB patients. Interestingly, serum levels of anti-LAM
antibodies were not detected in HIV patients without TB,
suggesting that these antibodies participate in protective
immuneresponsesagainstTBintheseindividuals[135].Our
experiments of invitro culturesofhuman PBMCsstimulated
with tuberculin comparing the role of autologous sera in
active TB patients (ATBP) demonstrated that the levels of
IgG antituberculin antibodies correlate with blocking of
the proliferation responses to tuberculin [136]. Such results
suggested that the polarity of responses could be produced
by either Th1 or Th2 immunity. In this regard, two diﬀerent
forms of leprosy correlate with Th1 or Th2 polarity of
the immune response [137, 138]. In tuberculoid leprosy,
patients mount a strong Th1-type cell-mediated immune-
response producing interferon-γ and IL-2 in lesions and
localize the infection, restricting the growth of the bacteria.
While in lepromatous leprosy, a widely disseminated form
of the infection is associated with a Th2 cytokine response
with decreased cell-mediated immunity [139]. It remains
to be determined if the same polarity exists in high-
risk latent TB (LTBI) contacts that produce high levels of
antituberculin IgG antibodies [136, 140, 141]. The absence
of a positive tuberculin skin test (TST) has also been
described in immunocompetent anergic patients diagnosed
withactiveTB,andtheinabilitytomountanantigen-speciﬁc
delayed-type hypersensitivity (DTH) response to PPD was
shown to be associated with a defective T cell response
including an antigen-speciﬁc impaired ability to produce
IL-2 and to proliferate in response to the PPD [136, 142]
regardless of prior BCG vaccination status [143]. These
ﬁndings could be due to a defective phosphorylation of T
cell receptor (TCR) leading to a defective activation of ZAP-
70 and MAPK proteins related to IL-2 gene transcription
and protein production after antigen stimulation of T cells
[144]. Additionally, a decrease of the γδT cells subset [11],
ad e c r e a s eo fI F N - γ production, an increase of IL-10 produc-
tioninresponsetoPPD[145],andafailureoftheautophagic
control by macrophages have been associated with anergy in
ATBI [146]. In previous studies, we analyzed the antibody
proﬁles to explain the presence of false negative or anergy
to TST responses in high-risk individuals without active TB
infection. Our results showed that regardless of the result
of the TST, antituberculin antibody titers correlate with the
protection from active TB and that the presence of high
antituberculin antibody titers is a reliable indicator of latent
infection. Importantly, high levels of antituberculin isotype
IgG3 antibodies could prevent the reactivation of the disease
in high-risk individuals [147].
In addition, studies in Mexican-Amerindian ethnic
groups have reported that IgG anti-Ag85 antibodies had
beneﬁcial eﬀects in the clinical outcome of pulmonary
tuberculosis [148].
Studies in mice have demonstrated that immunotherapy
with monoclonal antibodies speciﬁc to anti-Mtb surface
antigensreducesthesystemicinfectionandprolongssurvival
of mice infected with Mtb [149, 150].
Furthermore, recent studies demonstrate that passive
serum therapy with human polyspeciﬁc IgG protects mice
from Mtb Infection [151].
Recentﬁndingsdemonstratedthatintranasalinoculation
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antigen signiﬁcantly reduces the infection with the H37Rv
Mtb strain in CD89 transgenic mice [152].
Several mechanisms have been proposed by which anti-
bodies could mediate protective eﬀects against mycobacte-
rial infections. These mechanisms include the interference
of mycobacterial adhesion to cells possibly mediated by
antibodies speciﬁc to surface structural antigens of Mtb,
limiting the establishment or dissemination of Mtb infection
to other cells or tissues. The interference of adhesion
mediated by antibodies was demonstrated in experimental
assays in which the preincubation of Mtb with anti-LAM
antibodies inhibited the attachment to human macrophages
[153]. Other proposed mechanisms are the enhancing of
phagosome-lysosome fusion [154], bacterial products or
toxins neutralization, and cellular- or complement-mediated
bacterial lysis [154].
We consider that it is relevant to develop experimental
strategies to understand the role of humoral responses in
the outcome of mycobacterial infections. Functional studies
in both human and animals have revealed signiﬁcant results
about the protective eﬀect of antibodies. Finally, the studies
of passive immunotherapy using monoclonal antibodies
against speciﬁc Mtb antigens in transgenic mice are critical
to understand the molecular mechanisms that promote
antibody-mediated protection.
It is important to mention that the BCG vaccine devel-
oped one century ago remains one of the most widely
used vaccines. However, with the exemption of tuberculosis
meningitis in children, its capacity to protect the population
against Mtb infection is controversial because randomized
trials reported an important variation of protection from
zero to 80% [155]. All attempts to replace BCG have
achieved poor success due to our incomplete knowledge of
mechanisms of Mtb immunity.
7. Factors That Contribute to the Lack of
Control of Mtb Infection
7.1. Mechanisms of Mtb Evasion. Pathogens like Mtb have
evolved complex mechanisms to evade, divert, or subvert
immune responses. Mtb is one of the most successful human
pathogens. Diﬀerent from other pathogens, Mtb infection
can persist in the host for long periods in a dormant or
latent state, even in a fully functioning immune system. TB
immunity is mediated by Th1-type responses, nevertheless
this response is apparently not enough to deﬁnitively eradi-
cate the chronic infection nor the latent bacilli. Within the
strategies of Mtb to evade or subvert immune responses,
the best documented mechanisms are those that avoid the
elimination of the bacilli within macrophages and those that
interfere with an adequate antigen presentation for T cell
activation.
Macrophages are the major cell type infected by Mtb
in vivo, and they are the site of intracellular replication of
the mycobacteria. It is well documented that Mtb inhibits
the phagosome maturation and its fusion with the lysosome
in infected macrophages [156]. Mycobacterial phagosomes
retain GTPase markers of early endosomes such as Rab5,
and they limit the acquisition of late endosome markers
such as Rab7, leading to the arrest of phagosome maturation
[157]. In addition, some studies show that mycobacterial
phagosomes failed to acquire the vacuolar H+-ATPase that is
necessary for the phagosome acidiﬁcation [158]. Retention
of the tryptophan aspartate-rich coat protein (TACO) in
the surface of mycobacteria-containing phagosomes also
participates in the inhibition of the lysosome fusion with
the phagosome, which avoids the destruction of mycobac-
teria by the lysosomal enzymes [159, 160]. As we men-
tioned before, NO and RNIs are potent antimycobacterial
species produced within macrophages by the activity of
NOS2. Mtb has a sophisticated mechanism in which sev-
eral enzymes such as peroxiredoxin alkyl hydroperoxide
reductase subunit C (AhpC), dihydrolipoamide dehydro-
genase (Lpd) dihydrolipoamide succinyltransferase (SucB),
or thioredoxin-like AhpD are complexed to constitute a
nicotinamide-adenine-dinucleotide (reduced-) dependent
peroxidase and peroxynitrite reductase, generating an anti-
oxidant defense that confers RNIs resistance [161]. All these
mechanisms account for the survival and propagation of
mycobacteria within infected macrophages.
Another survival strategy of Mtb within the host is to
prevent the recognition of infected macrophages by CD4+
T cells, inhibiting MHC class II processing and presentation.
It has been described that the 19KDa lipoprotein antigen of
Mtb induces the downregulation of MHC class II molecule
expression in infected macrophages presumably due to the
excessive TLR2 stimulation. Since TLR2 is not only present
in the surface of the macrophage but also present within the
phagosome, it seems that chronically infected macrophages
constantly downregulate MHC class II molecules by
intraphagosomal TRL2 stimulation [42, 162, 163]. The IL-10
secretion from infected macrophages inhibits cathepsin S, a
protease necessary for the invariant chain degradation and
the proper loading of class II molecules and subsequent
surface expression [164].
An interesting emerging theme is the potential regu-
lation of autophagy during Mtb infection. Autophagy is
a homeostatic mechanism that involves the autodigestion
and turnover of long-lived cytoplasmic macromolecules and
organelles [165, 166]. It has been demonstrated that phys-
iological IFNγ or pharmacological induction of autophagy
promotes mycobacterial phagosome maturation and inhi-
bition of mycobacterial survival in infected macrophages
[166]. More recently, the mycobacterial gene eis (enhanced
intracellular bacterial survival) has been implicated in the
inhibition of autophagy in infected macrophages [167]. The
comprehensive mechanisms of autophagy and its potential
contribution to the regulation of Mtb infection warrant
further investigation.
Recent studies have demonstrated that DCs are also
infected with Mtb during mice experimental infection [168].
Mice airway immunization induces a delay in the expression
of costimulatory molecules (maturation) in DC and a delay
in the migration to the mediastinal lymph nodes (MLN)
where they begin to appear 14 days after immunization
and peak at day 21, in stark contrast to other soluble or
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mature DCs arrive to the MLN 24–48h after immunization.
This suggests that mycobacteria exert mechanisms that
actively inhibit DC functions and the onset of adaptive
immune responses [168, 169].
TherelevantparticipationofTh1-typeimmuneresponse
in the control of Mtb infection is clearly evident in the
altered genetic pathways for both the IFNγ and IL-12 axis
[170]. Mtb has developed many strategies to overcome this
adaptive immune response. Data from many laboratories
have documented the delay in the onset of adaptive immune
response against Mtb both in mice model and in humans
[171], nevertheless, the exact mechanisms that explain this
delayed response are not well understood.
Speciﬁc CD4+ T cells are primed by DCs in the MLN,
then they proliferate and migrate to the lung to eliminate
the mycobacteria [114]. Unlike the T cell involvement in
infections with other pathogens that enter through the
airways, in Mtb infection the speciﬁc T cells begin to appear
in the lung 14 days after aerosol infection [113]. This is
particularly intriguing since systemic peripheral response by
means of DTH assays is clearly seen 3 days after inoculation,
meaning that a delayed adaptive immune response is speciﬁc
of the Mtb target organ, the lung [168, 171]. In addition to
the delay in the onset of speciﬁc T cell response in the lung,
thepresenceofspeciﬁcTcellswithineﬃcientactivationphe-
notype or exhaustion phenotype has been described [172,
173]. Airborne infection of mice with the virulent strain
H37Rv triggered a considerable and progressive increase
in PD-1 positive T cells, both in the MLN and the lung
[174].Moreover,peripheralbloodorpleuralﬂuidfromMtb-
infected individuals also contained high numbers of PD-1+
T cells [173]. In addition, a mice model suggests that the
percentage of eﬀector IFN-γ producing CD4+ speciﬁc T cells
inthelungdisplaysprogressivedecreaseduringinfectionthat
correlateswiththedownmodulationofantigenexpressionby
mycobacteria [172]. It has been proposed that Mtb promotes
as u b o p t i m a le ﬀector function of CD4+ T cells as another
evasion mechanism; however, future functional assays are
needed to determine the possible mechanisms implicated in
this phenomenon.
7.2.TuberculosisinPatientswithInﬂammatoryImmune-Med-
iated Diseases. Several epidemiologic studies have shown
that rheumatoid arthritis (RA), systemic lupus erythemato-
sus (SLE), and other autoimmune disease patients have an
increased risk of bacterial and mycobacterial infections com-
pared with the general population, possibly due to immune
system innate or acquired defects, but certainly also due to
the use of immunosuppressive drugs. In the clinical setting,
itisdiﬃculttoseparatetheriskderivedfromthediseaseitself
from the risk conferred by the use of immunosuppressive
drugs, hence, all patients with autoimmune diseases require
adequate TB prophylaxis and a high index of suspicion
for TB infections because in these patients there is higher
index of extrapulmonary TB (up to 52% in some case
series), and the clinical picture may mimic a disease ﬂare
[175–177].
7.2.1. Tumor Necrosis Factor Antagonists and Risk of Mycobac-
terium tuberculosis Infection. Tumor necrosis factor antag-
onists have been a major advancement in the treatment of
several immune-mediated inﬂammatory diseases, including
rheumatoid arthritis (RA), ankylosing spondylitis (AS),
Crohn’sdisease,psoriaticarthritis,andpsoriasis.Thesedrugs
include chimerical human-murine monoclonal antibodies
(inﬂiximab), fully human monoclonal antibodies (adali-
mumab, golimumab), pegylated recombinant humanized
antibody Fab fragment against TNF (certolizumab), and a
soluble dimeric fusion protein that acts as a TNF receptor
(etanercept). They have been recognized as a risk factor for
active tuberculosis, independently of the underlying disease,
since it has been observed in patients with several inﬂam-
matory diseases [178]. Most of the available information is
about patients with rheumatoid arthritis, in whom the risk
of tuberculosis is 4–10-fold increased with the use of TNF
antagonists [179–181]. The disease pattern in these patients
is characterized by a high rate of extrapulmonary (56–62%)
and disseminated disease (24–28%) [182].
The ﬁve currently FDA-approved TNFα antagonists
diﬀer substantially in their structure and pharmacokinetics
[183]. These functional diﬀerences may have important
implications for both their eﬀectiveness and their adverse
event proﬁle. It is clear from several cohort studies that
TB incidence rates are higher with the use of inﬂiximab
and adalimumab compared with etanercept, and despite
screening and treatment guidelines, recent studies still show
this tendency. In a French biotherapy registry, the standard-
ized incidence ratio (SIR) was 18.6TB cases for patients
treated with inﬂiximab, 29.3TB cases for patients treated
with adalimumab, and 1.8TB cases for patients treated
with etanercept [184]. In the British Society for Rheuma-
tology Biologics Register, the rate of TB was higher for
adalimumab (144 events/100,000 person/years) and inﬂix-
imab (136/100,000 person/years) than for etanercept-treated
patients (39/100,000 person/years) [181]. Golimumab and
certolizumab seem to share the risk to develop TB. Although
no comparative studies have been published yet, several TB
cases have been reported in the clinical trials that have eval-
uated these drugs [185–187]. Several studies have revealed
thatmostTBcasesaredetectedwithintheﬁrstfewmonthsof
the treatment with inﬂiximab but at a stable rate throughout
the treatment with etanercept, suggesting that TB cases
associated with inﬂiximab may be due to reactivation of
latent disease, while TB cases associated with etanercept may
be due to both reactivation and primary infection [181].
7.2.2.MechanismsThatLeadtoIncreasedRiskofActiveTuber-
culosis Infection. It is evident that TNF-α plays a relevant
role in the defense against Mtb; therefore, it is expected
that blockade of the eﬀects of this molecule would alter
substantially the immune response to Mtb. Many studies
have demonstrated that TNF-α blockers have signiﬁcant
eﬀects on various immune cells, both in their activation and
responses. These eﬀects have an impact on innate and adap-
tive immune responses to many microorganisms, including
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the eﬀects of anti-TNF drugs in the immunopathogenesis of
TB have shown variable and even controversial results.
(a) Eﬀects on Phagosome Maturation and Autophagy. There
are experimental data that indicate that TNF blockers ham-
per phagosome maturation. Activation of macrophages with
IFN-γ inducesmaturationandacidiﬁcationofmycobacteria-
containing phagosomes, leading to increased intracellular
killing by macrophages in vitro [16, 188] Harris et al.
showed that this IFN-γ-induced increase in phagosome
maturation is inhibited in human macrophages exposed to
the TNF blockers adalimumab and inﬂiximab but not in
those exposed to etanercept; in addition, monocyte-derived
macrophage pretreatment with TNF induces phagosome
maturation [189].
In previous sections of this review, we discussed the
potential role of autophagy during Mtb infection. Physio-
logical IFN-γ or pharmacological induction of autophagy
promotes mycobacterial phagosome maturation and inhibi-
tion of mycobacterial survival in infected macrophages [166,
167]. Since, IFN-γ-induced phagosome maturation depends
upon autocrine TNF secretion and there are some studies
that suggest that TNF can induce autophagy [190–192], it is
possible that TNF blockers may also inhibit autophagy.
(b)EﬀectsonTCells. Severalstudieshaveexploredtheeﬀects
of TNF-α blockers on apoptosis on immune cells, showing
variable results. There are studies that show that inﬂiximab
induces apoptosis in activated but not resting T cells both in
vitro and in vivo in patients with Crohn’s disease [193, 194].
In addition, CD8+ T cells, that mediate Mtb-infected-
macrophage cell death by perforin and granulysin release,
candiebycomplement-dependentcytotoxicity(CDC)when
exposed to inﬂiximab [195].
OthermodelsusinghumanJurkatTcelllinesthatexpress
transmembrane tumor necrosis factor (tmTNF) have shown
that inﬂiximab and adalimumab, increases the CDC, and
inﬂiximab, adalimumab and etanercept can induce anti-
body-dependent cell-mediated cytotoxicity (ADCC) when
tmTNF-expressing Jurkat cells are added to lymphocytes
isolated from peripheral blood [196, 197].
Saliu et al. [198] showed that activation of T cells can
be modiﬁed by TNF blockers; they incubated whole blood
from TST positive donors with inﬂiximab and adalimumab
and observed a signiﬁcant decrease in the proportion of
activated (CD69+) CD4+ T cells responding to Mtb and also
a signiﬁcant reduction in the antigen-induced secretion of
IFN-γ and IL-10. Etanercept did not show similar results.
A similar experiment by Hamdi et al. [199] showed that
inﬂiximab and adalimumab inhibited PBMC proliferation
from patients with previous TB or LTBI in response to PPD
and other antigens. In addition, in patients that showed nor-
mal proliferative or IFNγ responses to PPD, treatment
with TNF blockers left PPD-speciﬁc proliferative response
unaltered but signiﬁcantly reduced the number of PPD-
speciﬁc IFNγ-producing cells. The decreases were similar
after treatment with inﬂiximab or etanercept and were inde-
pendent of the underlying disease (rheumatoid arthritis,
spondyloarthropathy, or Crohn’s disease). These results only
partially explain the diﬀerences in the Mtb infection rates in
patients treated with diﬀerent TNF-α-blockers.
In contrast with these results, other studies have shown
that treatment of patients with etanercept or inﬂiximab can
signiﬁcantlyenhancetheproliferationandIFN-γ production
of PPD-stimulated PBMC, including CD45RA CD4+ T cells.
These controversial results may be explained, in part, by
methodological diﬀerences, heterogeneity of the diseases, or
the dual role of TNF-α in Mtb infection [200–203].
(c) Eﬀects on Dendritic Cells and Monocytes. Etanercept can
induce apoptosis of dermal DCs in plaques of psoriatic
patients [204], while adalimumab and inﬂiximab can induce
apoptosis in lipopolysaccharide-stimulated human CD33+
blood monocytes [205].
8. Concluding Remarks
The eﬃcient and dynamic interaction between innate and
acquiredimmune responses is criticalin theestablishmentof
host-Mtb interaction and in the control of infection. Several
cell types and molecules produced early in response to Mtb
determine the establishment of the primary infection and
the outcome of the disease after dissemination of Mtb. In
this context, signaling mediated by a redundant interaction
between Mtb and TLRs frequently induces an eﬃcient innate
activation of infected macrophages resulting in enhanced
bacterial killing. However, future studies should be focused
on the role of the TLRs and other innate receptors and the
connection of innate and adaptive responses in order to
clarify their role in the generation of latent TB states or in
the outcome of clinically active Mtb infection. In addition
to the innate and T-cell-mediated immunity, it is important
to revisit the role of humoral immunity in the generation
of antibody-mediated protective responses in Mtb infection.
Transgenicmicewithhumanimmunomodulatorymolecules
should be used to prove the importance of immunotherapy
in the control of mycobacterial infections. In this context, it
iswellknownthatTh-1cellsarehighlyproinﬂammatoryand
are known to be involved in the progression of autoimmune
diseases, whereas Th2 are involved in allergy. There is no
doubt that immunity to Mtb depends on Th1-cell activity
(IFN-γ and IL-12 and the production of TNF-α), but Th1
immunityaloneisnotsuﬃcienttoprotectthehostfromMtb
infection, development of the disease, or dissemination.
The role of additional T cell subpopulations during TB
infection has been extensively described including Th17,
Treg, Th22, and follicular T cells. Th17 cells are capable
of inducing tissue inﬂammation and autoimmunity. Nev-
ertheless, the precise contribution of these non-Th1/Th2
T cell subsets in TB has not been elucidated. On the
other hand, cytokines related to IL-10 classically have been
involved in the stimulation of Th2 responses and antibody
production. However the cytokine IL-19 has an important
immunoregulatory role. In this regard, the importance of
IL-19, IL-27, and IL-35 in infections such as TB and in
autoimmune diseases is under investigation. TNF-α plays aClinical and Developmental Immunology 11
relevant role in the defense against Mtb. Several studies have
established that TNF-α blockers have deleterious eﬀects on
thedevelopmentofeﬀectiveimmuneresponses.Theseeﬀects
have an impact on innate and adaptive immune responses to
many microorganisms, including Mtb. Nevertheless, exper-
imental studies that have explored the eﬀects of anti-TNF
drugsintheimmunopathogenesisofTBhaveshownvariable
and even controversial results.
The role of cellular and humoral immunity is important
in the design of new vaccines against Mtb. However, further
research focused on the mechanisms of bacterial control
in individuals exposed to but not infected with Mtb and
the capacity to develop latent forms of infection is needed.
It is possible that the capacity to develop LTBI might be
inﬂuenced by the continuous exposure to environmental
mycobacteria or the continuous exposure to microbiome
that is critical to induce the expression of genes associ-
ated with inﬂammation and antimicrobial defense. Even
though the mechanisms implicated in the pathogenesis of
Mtb infection are complex, a better understanding of the
molecular and cellular responses against Mtb can be helpful
in the development of novel therapeutic and prophylactic
strategies.
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